- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Patrick Gleason Speaks on Trends in Prescription Drug Spending
Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space.
Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space. “It suffices to say that it’s pharmaceutical manufacturer price increases that are driving or fueling the specialty drug trend with an increase in utilization, and we foresee this growing in the future,” Dr Gleason said. “What’s really interesting is to look at the expenditures of specialty drugs not just on the pharmacy benefit, but the medical benefit.”
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
